Allopurinol-induced DRESS syndrome

Israel Medical Association Journal

Volumn 7, Issue 10, 2005, Pages 656-660

  Markel, Arie ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Allopurinol hyperensitivity; Allopurinol toxicity; DRESS syndrome; Drug hypersensitivity; Hyperuricemia

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; CARBAMAZEPINE; CORTICOSTEROID; OXIPURINOL; PHENOBARBITAL; PHENYTOIN; SULFONAMIDE; THIAZIDE DIURETIC AGENT; URIC ACID;

ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOACCUMULATION; CLINICAL FEATURE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRESS SYNDROME; DRUG ACETYLATION; DRUG CLEARANCE; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; ENZYME DEFECT; EOSINOPHILIA; EXFOLIATIVE DERMATITIS; FACE EDEMA; GENETIC PREDISPOSITION; GOUT; HIGH RISK POPULATION; HUMAN; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LYMPHADENOPATHY; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOSIS; MONONUCLEOSIS; NEPHROLITHIASIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SKIN MANIFESTATION; SYSTEMIC DISEASE; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; URIC ACID BLOOD LEVEL; VASCULITIS; VIRUS INFECTION;

ALLOPURINOL; DRUG HYPERSENSITIVITY; GOUT; GOUT SUPPRESSANTS; HUMANS;

EID: 27144533642     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Wortmann RL. Disorders of purine and pyrimidine metabolism. In: Braunwald E, Fauci AS, Kasper DC, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. Vol 2, 15th edn. New York: McGraw-Hill, 2005:2268-73.
2. Zinger JZ, Wallace SL. The allopurinol hypersensitivity syndrome Unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
3. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
4. Roberts LJ, Morrow JD. Analgesic-antipyretics and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Goodman Gilman A, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th edn. New York: McGraw-Hill, 2001:687-732.
5. Shaw RK, Shukman RN, Davidson JK, Rall BP, Frei E. Studies with the experimental antitumor agent 4-amino pyrazolo (3.4-d) pyrimidine. Cancer 1960;13:482-9.
6. Antigout drugs. In: Sweetman SC, ed. Martindale - The Complete Drug Reference. 33rd edn. London/Chicago: Pharmaceutical Press 2002:397-43.
7. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS Syndrome): an update. Dermatology 2003;2006:353-6.
8. Sullivan JR. The drug hypersensitivity syndrome. Arch Dermatol 2001;137:57-64.
9. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998;134:874-5.
10. Ichiche M, Kiesch N, De Bels D. DRESS syndrome associated with HHV-6 reactivation. Eur J Intern Med 2003;14:498-500.
11. Alonso CG, Fuertes MA, de Dios PS, Arevalo VA. DRESS syndrome associated with nevirapine therapy. Arch Intern Med 2001;161:2501-2.
12. Valencak J, Ortiz-Urda S, Heere-Ress E, Kunstfeld R, Base W. Carbamazepine-induced DRESS syndrome with recurrent fever and exanthema. Int J Dermatol 2004;43:51-4.
13. Roujeau JC, Stern RS. Severe adverse reactions to drugs. N Engl J Med 1994;331:1272-85.
14. Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001;137:301-4.
15. Khoo BP, Leow YH. A review of inpatients with adverse drug reactions to allopurinol. Singapore Med J 2000;41:156-60.
16. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 1981;40:245-9.
17. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337-43.
18. Young JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity: association with thiazides and prior renal compromise. Arch Intern Med 1974;134:553-8.
19. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical Aspects of Immunology. Oxford: Blackwell, 1975:761
20. Galli SJ, Lantz CS. Allergy. In: Paul WE, ed Fundamental Immunology. 4th edn Philadelphia/New York: Lippincott Raven, 1999:1127-74.
21. Grussendorf M, Andrassy K, Waldherr R, Ritz E. Systemic hypersensitivity to allopurinol with acute interstitial nephritis. Am J Nephrol 1981;1:105-9.
22. Kantor GL. Toxic epidermal necrolyisis, azotemia, and death after allopurinol therapy. JAMA 1970;212:478-9.
23. McKendrick MW, Geddes AM. Allopurinol hypersensitivity. Br Med J 1979;i:988.
24. Lockard O Jr, Harmon C, Nolph K, Irvin W. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 1976;85:333-5.
25. Braden GL, Warzynski MJ, Golightly M, Ballow M. Cell-mediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994;70:145-51.
26. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG. Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981;95:588-90.
27. Webster E, Panush RS. Allopurinol hypersensitivity in a patient with severe, chronic, tophaceous gout. Arthritis Rheum 1985;28: 707-9.
28. Mitchel BS, Kelley WN. Purinogenic immunodeficiency diseases: clinical features and molecular mechanisms. Ann Intern Med 1980;92:826-31.
29. Rieder M, Shear N, Kanee A, Tang B, Spielberg S. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13-17.
30. Vasquez-Mellado J, Meoño Morales E, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
31. Hellman C, Lonnkvist K, Hedlin G, Hallden G, Lundahl J. Down-regulated IL-5 receptor expression on peripheral blood eosinophils from budesonide-treated children with asthma. Allergy 2002;57:323-8.
32. Chopra S, Levell NJ, Cowley G, Gilkes JJ. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996;134:1109-12.
33. Vittorio CC, Muglia JJ. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995;155:2285-90.
34. Redondo P, de Felipe I, de la Pena A, Aramendia JM, Vanaclocha V. Drug-induced hypersensitivity syndrome and toxic epidermal necrolyisis. Treatment with N-acetylcysteine. Br J Dermatol 1997;136:645-6.
35. McDonald J, Fam AG, Paton T, Senn J. Allopurinol hypersensitivity in a patient with coexistent systemic lupus erythematosus and tophaceous gout. J Rheumatol 1988;15:865-8.
36. Gillot TJ, Whalletti A. Zaphiropoulos G. Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity. Rheumatology 1999;38:85-6.
37. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8
38. Schumacher MJ, Copeland JG. Intravenous desensitization to allopurinol in a heart transplant patient with gout. Ann Allergy Asthma Immunol 2004;92:374-6.
39. Terkeltaub RA. Gout. N Engl J Med 2003;349:1647-55.